Evidence map›Paper›PMID 37938521›Full record

ArticleDrugs & aging2023

Polypharmacy and Antibody Response to SARS-CoV-2 Vaccination in Residents of Long-Term Care Facilities: The GeroCovid Vax Study.

Caterina Trevisan, Labjona Haxhiaj, Alba Malara, Angela Abbatecola, Giorgio Fedele, Annapina Palmieri, Pasqualina Leone, Ilaria Schiavoni, Paola Stefanelli, Stefania Maggi and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Drugs & aging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Caterina Trevisan *Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
Labjona Haxhiaj *Department of Medicine, University of Padua, Via Giustiniani 2, 35128, Padua, Italy. labjona92@gmail.com.ORCID 0009-0002-2320-5933
Alba MalaraANASTE Humanitas Foundation, Rome, Italy.
Angela AbbatecolaAlzheimer's Disease Day Clinic, Azienda Sanitaria Locale, Frosinone, Italy.
Giorgio FedeleDepartment of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
Annapina PalmieriDepartment of Cardiovascular, Endocrine‑Metabolic Diseases and Aging, Istituto Superiore di Sanità, Rome, Italy.
Pasqualina LeoneDepartment of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
Ilaria SchiavoniDepartment of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
Paola StefanelliDepartment of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
Stefania MaggiInstitute of Neuroscience, National Research Council, Padua, Italy.
Giuseppe SergiDepartment of Medicine, University of Padua, Via Giustiniani 2, 35128, Padua, Italy.
Stefano VolpatoDepartment of Medical Sciences, University of Ferrara, Ferrara, Italy.
Raffaele Antonelli IncalziCampus Bio-Medico University, Rome, Italy.
Graziano OnderUniversità Cattolica del Sacro Cuore, Rome, Italy.
GeroCovid Vax Working Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivePolypharmacy is common in older adults, particularly among those living in long-term care facilities. This condition represents a marker of clinical complexity and might directly affect the immunological response. However, there are limited data on the association of polypharmacy with vaccine immunogenicity. This study evaluated the immune response to anti-SARS-CoV-2 vaccines in older residents of long-term care facilities as a function of the number of medications used.

methodsIn 478 long-term care facility residents participating in the GeroCovid Vax study, we assessed SARS-CoV-2 trimeric S IgG levels through chemiluminescent assays before the vaccination and after 2, 6, and 12 months. A booster dose was administered between 6- and 12-month assessments. Sociodemographic information and data on chronic diseases and medications were derived from medical records. Based on the number of daily medications, residents were classified into the no polypharmacy (zero to four medications), polypharmacy (five to nine medications), and hyperpolypharmacy (ten or more medications) groups.

resultsIn the sample (mean age 82.1 years, 69.2% female), 200 (41.8%) residents were taking five or fewer medications/day (no polypharmacy), 229 (47.9%) had polypharmacy, and 49 (10.3%) had hyperpolypharmacy. Using linear mixed models adjusted for potential confounders, we found that hyperpolypharmacy was associated with a steeper antibody decline after 6 months from the first vaccine dose administration (β = - 0.29, 95% confidence interval - 0.54, - 0.03, p = 0.03) than no polypharmacy, while no significant differences were observed at 12 months.

conclusionsThe humoral immune response to SARS-CoV-2 vaccination of older residents showed only slight changes as a function of the number of medications taken. Although it seemed less durable among older residents with hyperpolypharmacy, the booster dose administration equalized such a difference.

Indexed as

COVID-19COVID-19 VaccinesAgedAged, 80 and overAntibody FormationFemaleHumansLong-Term CareMalePolypharmacySARS-CoV-2VaccinationCOVID-19 Vaccines

Identifiers

PMID37938521

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.